IL1B and influenza: Prevention of platelet aggregation using other compounds has also been shown to improve survival in mouse models of severe influenza and is associated with reduced inflammation, reduction in proinflammatory cytokine levels (IL-1β, IL-6, TNF-α, and MIP-2) and reduced platelet activation [177].